Pfizer Inc.
PFE Healthcare Drug Manufacturers General
Pfizer Inc.’s revenue for fiscal 2025 (year ended December 2025) was $62.6 billion, down 1.65% from fiscal 2024. In the quarter to June 2026, revenue grew 2.60%, EPS fell 107.8%, free cash flow grew 125.2% and total debt rose 2.26%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years; insiders bought in the last twelve months.
Follow PFE
Pfizer Inc. (PFE) EBITDA
Pfizer Inc.'s EBITDA for fiscal 2025 was $20.8B, up 7.27% from $19.4B in fiscal 2024. Over the twelve months to 30 June 2026 it was $20.4B. Over the past ten years it has ranged from $7.6B (fiscal 2023) to $40.9B (fiscal 2022); the current reading is higher than 82% of that period. Pfizer Inc. ranks 6th of 20 Drug Manufacturers General companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $20.8B | 7.27% |
| FY2024 | $19.4B | 156.63% |
| FY2023 | $7.6B | (81.47%) |
| FY2022 | $40.9B | 65.91% |
| FY2021 | $24.6B | 90.43% |
| FY2020 | $12.9B | 3.74% |
| FY2019 | $12.5B | 5.44% |
| FY2018 | $11.8B | (40.86%) |
| FY2017 | $20.0B | 11.67% |
| FY2016 | $17.9B | 5.42% |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | $4.7B | (16.99%) |
| Mar 2026 | $5.6B | 23.82% |
| Dec 2025 | $4.6B | (17.30%) |
| Sep 2025 | $5.5B | 1.94% |
| 42 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| NVO Novo Nordisk A/S compare | $26.5B |
| NVS Novartis AG compare | $22.5B |
| PFE Pfizer Inc. | $20.4B |
| AZN AstraZeneca PLC compare | $20.3B |
| AMGN Amgen Inc. compare | $16.5B |
| BMY Bristol Myers Squibb Company compare | $15.1B |
| GSK GSK PLC Sponsored ADR compare | $12.8B |
| SNY Sanofi compare | $10.4B |
| GILD Gilead Sciences, Inc. compare | $262.0M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on PFE
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement